Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Novartis scores a quick FDA OK for its new cancer drug Lutathera, picked up in $4B buyout
Novartis scores a quick FDA OK for its new cancer drug Lutathera, picked up in $4B buyout
Novartis scores a quick FDA OK for its new cancer drug Lutathera, picked up in $4B buyout
Submitted by
admin
on January 26, 2018 - 5:25pm
Source:
Endpoints
News Tags:
Novartis
Lutathera
FDA
neuroendocrine tumors
Headline:
Novartis scores a quick FDA OK for its new cancer drug Lutathera, picked up in $4B buyout
Do Not Allow Advertisers to Use My Personal information
